<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43646">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02046525</url>
  </required_header>
  <id_info>
    <org_study_id>201312022</org_study_id>
    <secondary_id>1U54CK000162</secondary_id>
    <nct_id>NCT02046525</nct_id>
  </id_info>
  <brief_title>Autologous Fecal Therapy</brief_title>
  <official_title>Restoration of the Fecal Microbiome After Antimicrobial Exposure With Autologous Fecal Flora Restoration Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ten healthy volunteers will be recruited to receive either an autologous stool transplant or
      a saline enema to determine if autologous fecal microbiota therapy will be able to rapidly,
      and safely, restore a patient's fecal microbiome after antimicrobial exposure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>microbiome composition</measure>
    <time_frame>90 days after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>microbial community composition (taxa that are present) and structure (abundance of taxa)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Infectious Disease of Digestive Tract</condition>
  <arm_group>
    <arm_group_label>Auto fecal microbitoa therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous fecal microbiota therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline enema</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline enema</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous fecal microbiota therapy</intervention_name>
    <arm_group_label>Auto fecal microbitoa therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Adults 18-70 years of age-

        Exclusion Criteria:

        history of allergic reaction to beta-lactam antimicrobials; any non-topical antimicrobial
        exposure or tube feeds as a primary source of nutrition in the past six months; pregnant
        or risk of becoming pregnant during the study period; gastroenteritis in the last 3
        months; incontinent of stool; prior resection or alteration of the stomach; small bowel,
        or colon; unwillingness to receive an enema/FMT; known colonization with an MDRO;
        anticipated change in diet or medications, or elective surgery, during the study period;
        or a history of an intestinal disorder -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sondra Seiler</last_name>
      <phone>314-454-8246</phone>
      <email>sseiler@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Erik Dubberke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fecal microbiota therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
